82 related articles for article (PubMed ID: 20637869)
1. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Joshi SA; Chavhan SS; Sawant KK
Eur J Pharm Biopharm; 2010 Oct; 76(2):189-99. PubMed ID: 20637869
[TBL] [Abstract][Full Text] [Related]
2. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles.
Yadav KS; Sawant KK
AAPS PharmSciTech; 2010 Sep; 11(3):1456-65. PubMed ID: 20842542
[TBL] [Abstract][Full Text] [Related]
3. Blood-Nanoparticle Interactions Create a Brain Delivery Superhighway for Doxorubicin.
Li Z; Kovshova T; Malinovskaya J; Knoll J; Shanehsazzadeh S; Osipova N; Chernysheva A; Melnikov P; Gelperina S; Wacker MG
Int J Nanomedicine; 2024; 19():2039-2056. PubMed ID: 38476274
[TBL] [Abstract][Full Text] [Related]
4. Nose-to-brain delivery of hesperidin nanoparticles loaded in-situ gel for neuroprotective action.
Bamankar S; Londhe V
Ann Pharm Fr; 2023 Nov; 81(6):985-996. PubMed ID: 37708993
[TBL] [Abstract][Full Text] [Related]
5. A new agent for contrast-enhanced intravascular ultrasound imaging in vitro: polybutylcyanoacrylate nanoparticles with drug-carrying capacity.
Wang C; Jiang H; Zhu J; Jin Y
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):218-228. PubMed ID: 38646876
[TBL] [Abstract][Full Text] [Related]
6. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
Yang ZZ; Zhang YQ; Wang ZZ; Wu K; Lou JN; Qi XR
Int J Pharm; 2013 Aug; 452(1-2):344-54. PubMed ID: 23680731
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease.
Ismail MF; Elmeshad AN; Salem NA
Int J Nanomedicine; 2013; 8():393-406. PubMed ID: 23378761
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
9. PLGA-based nanoparticles: an overview of biomedical applications.
Danhier F; Ansorena E; Silva JM; Coco R; Le Breton A; Préat V
J Control Release; 2012 Jul; 161(2):505-22. PubMed ID: 22353619
[TBL] [Abstract][Full Text] [Related]
10. Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer's disease.
Imam F; Mukhopadhyay S; Kothiyal P; Alshehri S; Saad Alharbi K; Afzal M; Iqbal M; Rashid Khan M; Khalid Anwer M; Ahmed Hattab Alanazi A; Ghanem Alqahtani A; Abdullah Alhamamah M
Saudi Pharm J; 2024 May; 32(5):102048. PubMed ID: 38585197
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-empowered therapeutics targeting neurodegenerative diseases.
Wang Z; Gonzalez KM; Cordova LE; Lu J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1907. PubMed ID: 37248794
[TBL] [Abstract][Full Text] [Related]
12. Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review.
Jalili C; Kiani A; Gholami M; Bahrehmand F; Fakhri S; Kakehbaraei S; Kakebaraei S
IET Nanobiotechnol; 2023 May; 17(3):154-170. PubMed ID: 36949020
[TBL] [Abstract][Full Text] [Related]
13. QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics.
Arora D; Bhatt S; Kumar M; Verma R; Taneja Y; Kaushal N; Tiwari A; Tiwari V; Alexiou A; Albogami S; Alotaibi SS; Mittal V; Singla RK; Kaushik D; Batiha GE
Front Aging Neurosci; 2022; 14():960246. PubMed ID: 36034142
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer targeting efficiency of Silibinin loaded Poly Caprolactone /Pluronic F68 Inhalable nanoparticles: In vitro and In vivo study.
Patel P; Raval M; Manvar A; Airao V; Bhatt V; Shah P
PLoS One; 2022; 17(5):e0267257. PubMed ID: 35560136
[TBL] [Abstract][Full Text] [Related]
15. PLGA nanoparticle preparations by emulsification and nanoprecipitation techniques: effects of formulation parameters.
Hernández-Giottonini KY; Rodríguez-Córdova RJ; Gutiérrez-Valenzuela CA; Peñuñuri-Miranda O; Zavala-Rivera P; Guerrero-Germán P; Lucero-Acuña A
RSC Adv; 2020 Jan; 10(8):4218-4231. PubMed ID: 35495261
[TBL] [Abstract][Full Text] [Related]
16. Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain.
Pardridge WM
Front Med Technol; 2020; 2():602236. PubMed ID: 35047884
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases.
Riccardi C; Napolitano F; Montesarchio D; Sampaolo S; Melone MAB
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834311
[TBL] [Abstract][Full Text] [Related]
18. Optimized Rivastigmine Nanoparticles Coated with Eudragit for Intranasal Application to Brain Delivery: Evaluation and Nasal Ciliotoxicity Studies.
Bhanderi M; Shah J; Gorain B; Nair AB; Jacob S; Asdaq SMB; Fattepur S; Alamri AS; Alsanie WF; Alhomrani M; Nagaraja S; Anwer MK
Materials (Basel); 2021 Oct; 14(21):. PubMed ID: 34771817
[TBL] [Abstract][Full Text] [Related]
19. Organ-on-a-chip technology for nanoparticle research.
Kang S; Park SE; Huh DD
Nano Converg; 2021 Jul; 8(1):20. PubMed ID: 34236537
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Targeted Delivery of Bufalin-Loaded Modified Albumin-Polymer Hybrid for Enhanced Antitumor Therapy and Attenuated Hemolysis Toxicity and Cardiotoxicity.
Xu Y; Tang L; Chen P; Chen M; Zheng M; Shi F; Wang Y
AAPS PharmSciTech; 2021 Apr; 22(4):137. PubMed ID: 33880681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
